Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31437151 | 0.83 | PDCD1 (0.31) | SLC6A3HDAC6 | |
| SCHEMBL15273696 | 0.79 | ALDH1A1 (0.41) | PDK1PDK2HTR2AHTR2CHDAC6 | |
| SCHEMBL26686537 | 0.77 | NR1H2 (0.42) | HDAC6 | |
| SCHEMBL1423019 | 0.75 | HTR2A (0.40) | PDK1PDK2HTR2AHTR2CLDHA | |
| SCHEMBL22275219 | 0.75 | ALDH1A1 (0.43) | HTR2AHTR2CLDHA | |
| SCHEMBL31389508 | 0.74 | ALDH1A1 (0.42) | HTR2AHTR2CLDHA | |
| SCHEMBL20228734 | 0.71 | HTR2A (0.38) | PDK1PDK2HTR2AHTR2CNTRK1 | |
| SCHEMBL16093626 | 0.70 | TACR1 (0.35) | HTR2A | |
| SCHEMBL22518543 | 0.70 | HTR2A (0.40) | PDK1PDK2HTR2AHTR2CHDAC6 | |
| SCHEMBL20645822 | 0.70 | RIPK1 (0.33) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009634-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION (US) | 2008-01-10 | — | — | US | claimed |
| US-20040242874-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION | 2004-12-02 | — | — | US | claimed |
| US-20080009634-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009634-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009634-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-7316917-B2 | Production of bicyclic-heteroaryl-2-carboxylic acids by selective enzymatic hydrolysis of a mixture of positional esters | WYETH HOLDINGS CORPORATION (US) | 2008-01-08 | — | — | US | disclosed |
| US-7276611-B2 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276611-B2 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276611-B2 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1626972-A1 | PROCESS FOR SYNTHESIZING ß-LACTAMASE INHIBITOR INTERMEDIATES | Wyeth Holdings Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20040242874-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION | 2004-12-02 | — | — | US | disclosed |
| WO-2004104008-A1 | PROCESS FOR SYNTHESIZING β-LACTAMASE INHIBITOR INTERMEDIATES | WYETH HOLDINGS CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040229324-A1 | Production of bicyclic-heteroaryl-2-carboxylic acids by selective enzymatic hydrolysis of a mixture of positional esters | WYETH HOLDINGS CORPORATION | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009634-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | COASY, DCXR, MGAM | PDK1 1267/4885PDK2 804/4885SLC6A3 4748/4885 |
| US-20040229324-A1 | Production of bicyclic-heteroaryl-2-carboxylic acids by selective enzymatic hydrolysis of a mixture of positional esters | COASY, CES2, CES1 | PDK1 833/4885PDK2 419/4885SLC6A3 4410/4885 |
| US-20040242874-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | COASY, DCXR, MGAM | PDK1 1224/4885PDK2 830/4885SLC6A3 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.